TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05139719: A Phase IIb, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With Progressive Fibrosing Interstitial Lung Disease

Sponsor: Sunshine Lake Pharma Co., Ltd. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 110 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT05139719 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05139719 Rescue Dossier →